Bausch & LombBLCO +2.58%77 Days Payable is 75.10 as of Mar. 2026, which is 5% above its 10-year median of 71.51. GuruFocus rates BLCO with a GF Score™ of 77/100 and a GF Value™ of $18.37 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 796 Medical Devices & Instruments companies, Bausch & Lomb ranks better than 54.15% on this metric.
The historical rank and industry rank for Bausch & Lomb's Days Payable or its related term are showing as below:
BLCO'
s Days Payable Range Over the Past 10 Years
Min: 51.89 Med: 71.51 Max: 99.66
Current: 74.18
During the past 8 years, Bausch & Lomb's highest Days Payable was 99.66. The lowest was 51.89. And the median was 71.51.
BLCO's Days Payable is ranked better than 54.15% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 68.14
vs BLCO: 74.18
Bausch & Lomb's Days Payable
declined
from Mar. 2025 (77.24) to Mar. 2026 (75.10).
It may suggest that Bausch & Lombaccelerated paying its suppliers.
Bausch & Lomb Days Payable Related Terms
Bausch & Lomb Days Payable Historical Data
* Premium members only.
The historical data trend for Bausch & Lomb's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Bausch & Lomb's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch & Lomb Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's Days Payable distribution charts can be found below:
* The bar in red indicates where Bausch & Lomb's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Bausch & Lomb's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch & Lomb (BLCO) has a Days Payable of 75.10 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bausch & Lomb and its competitors. This is near median its historical median of 71.51. Over the past decade, Bausch & Lomb's Days Payable has ranged from 51.89 to 99.66. According to the industry distribution chart, Bausch & Lomb ranks #365 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 45.9%.
Is Bausch & Lomb's Days Payable too high?
Bausch & Lomb's current Days Payable of 75.10 is near median its 10-year median of 71.51. Over the past 10 years, this metric has ranged from a low of 51.89 to a high of 99.66. The Medical Devices & Instruments industry median Days Payable is 68.14. Bausch & Lomb's value of 75.10 is 10.2% above this industry median. Based on the distribution chart, Bausch & Lomb ranks #365 out of 796 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bausch & Lomb has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bausch & Lomb's Days Payable compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bausch & Lomb ranks #365 out of 796 companies for Days Payable. This puts Bausch & Lomb in the upper half of its industry. The industry median Days Payable is 68.14. Bausch & Lomb's value of 75.10 is 10.2% above this benchmark. Historically, Bausch & Lomb's own Days Payable has ranged from 51.89 to 99.66 over the past decade. While the company's 10-year median is 71.51 vs. the industry median of 68.14, Bausch & Lomb has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.14, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bausch & Lomb's current Days Payable of 75.10 is 10.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bausch & Lomb and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bausch & Lomb's current Days Payable is 75.10, which is near median its own 10-year median of 71.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch & Lomb stock overvalued right now?
Based on GuruFocus' analysis, Bausch & Lomb (BLCO) is currently considered Modestly Undervalued. The stock's GF Value™ is $18.37, compared to a current price of $16.32 — trading 11.2% below its estimated fair value. The current Days Payable is 75.10, which is near median its 10-year median of 71.51 and 10.2% above the Medical Devices & Instruments industry median of 68.14. Bausch & Lomb's overall GF Score™ is 77/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Bausch & Lomb (BLCO), the current Days Payable is 75.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bausch & Lomb (BLCO) Overvalued in 2026?
Based on GuruFocus' analysis, Bausch & Lomb stock appears to be undervalued.
The current stock price of $16.32 is trading 11.2% below its estimated GF Value™ of $18.37.
GuruFocus considers Bausch & Lomb to be Modestly Undervalued.
Key valuation signals for BLCO:
Days Payable: 75.10 (near median its 10-year median of 71.51)
GF Value™: $18.37 vs. price of $16.32 (11.2% below fair value)
Industry Position: 10.2% above the Medical Devices & Instruments median (#365 of 796)
No single metric tells the full story. See the BLCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
77GF Score
Get the complete analysis for BLCO
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLCO has been successfully added to your 
